PerkinElmer posts growth in Q2
July 26, 2021 -- PerkinElmer posted revenue and operating income increases in its second quarter 2021. Read More
EMA takes positive stance on Moderna COVID-19 vaccine for adolescents
July 26, 2021 -- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has taken a positive position on marketing authorization for Moderna's COVID-19 vaccine for use in adolescents 12 years of age and older. Read More
Collaborative Drug Discovery launches new drug database
July 26, 2021 -- Collaborative Drug Discovery has launched a new database called BioHarmony that offers continually updated drug data from a variety of sources. Read More
Twist incorporates Molcure AI into antibody discovery efforts
July 26, 2021 -- Twist Bioscience announced that it has used Molcure's artificial intelligence (AI) technology to generate new cancer antibodies. Read More
Slingshot Biosciences raises $23M for synthetic cell platform
July 23, 2021 -- Slingshot Biosciences announced the closing of $23 million in series A financing to fund the company's synthetic cell products portfolio. Read More
Danaher reports earnings, revenue increases in Q2
July 23, 2021 -- Danaher announced earnings and revenue increases for its second quarter of 2021. Read More
Wheeler Bio launches as antibody biomanufacturing company
July 22, 2021 -- Biotechnology ecosystem company Alloy Therapeutics and investment firm Echo Investment Capital announced the launch of Wheeler Bio, a new biomanufacturing company. Read More
AavantiBio, Aldevron partner on gene therapy
July 21, 2021 -- Aldevron made a deal to supply plasmid DNA that will enable AavantiBio to advance its gene therapies for rare genetic diseases. Read More
Africa to get doses of Pfizer-BioNTech COVID-19 vaccine
July 21, 2021 -- Pfizer and BioNTech have signed a letter of intent with South Africa-based Biovac Institute to manufacture and distribute the companies' COVID-19 vaccine within the African Union. Read More
Kineta, Samsung Biologics partner on solid-tumor therapy
July 21, 2021 -- Samsung Biologics has inked a deal providing end-to-end development and manufacturing services to advance Kineta's anti-V-domain immunoglobulin suppressor of T-cell activation (VISTA) antibody being developed for the treatment of solid tumors. Read More
Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter